Owonikoko, T., Papadopoulos, K., Johnson, M. and al., et (2019) “Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1 Antibody, in Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-up Efficacy and Safety Data”, SKIN The Journal of Cutaneous Medicine, 3(2), p. 169. doi: 10.25251/skin.3.2.9.